Romiplostim as a transfusion saving strategy in 20 patients after heart or lung transplantation: a single centre before-after pilot study.

Mickael Vourc'hThomas SenageThierry LepoivreChristelle VolteauCamille FortuitSabine PattierGuillaume GuimbretiereJean-Christian RousselBertrand Rozec

Published in: Perfusion (2019)

Romiplostim did not significantly reduce platelet transfusion after heart or lung transplantation. Its relevance and safety in a global transfusion strategy remains to be studied in this setting in a large randomised study.

Keyphrases

cardiac surgery
heart failure
end stage renal disease
extracorporeal membrane oxygenation
sickle cell disease
clinical trial
ejection fraction
newly diagnosed
prognostic factors
acute kidney injury
atrial fibrillation
randomized controlled trial
patient reported outcomes
double blind